Eucast 2020 PDF

Preview

Summary

EUCAST...

Description

European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters Version 10.0, valid from 2020-01-01 This document should be cited as "The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0, 2020. http://www.eucast.org." Content Changes Notes Guidance on reading EUCAST Breakpoint Tables Dosages Information on technical uncertainty Enterobacterales Pseudomonas spp. Stenotrophomonas maltophilia Acinetobacter spp. Staphylococcus spp. Enterococcus spp. Streptococcus groups A, B, C and G Streptococcus pneumoniae Viridans group streptococci Haemophilus influenzae Moraxella catarrhalis Neisseria gonorrhoeae Neisseria meningitidis Gram-positive anaerobes Clostridioides difficile Gram-negative anaerobes Helicobacter pylori Listeria monocytogenes Pasteurella multocida Campylobacter jejuni and coli Corynebacterium spp. Aerococcus sanguinicola and urinae Kingella kingae Aeromonas spp. Burkholderia pseudomallei Burkholderia cepacia complex

Page 1 9 11 12 16 18 23 28 29 34 39 44 49 55 60 66 70 74 78 83 84 88 89 90 92 93 95 97 99 101 103

Additional information

Link to Guidance Document on Stenotrophomonas maltophilia

Link to Guidance Document on Burkholderia cepacia complex

Content Legionella pneumophila Mycobacterium tuberculosis Topical agents PK-PD (Non-species related) breakpoints Expert Rules Detection of Resistance Mechanisms Antimicrobial susceptibility tests on groups of organisms or agents for which there are no EUCAST breakpoints

Page 104 105 106 107 -

Additional information

Link to Guidance Document on Topical Agents Link to EUCAST Expert Rules Link to EUCAST Guidelines on Detection of Resistance Mechanisms Link to Guidance Document on how to test and interpret results when there are no breakpoints

European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters Version 10.0, valid from 2020-01-01 Version 10.0, 2020-01-01

Changes (cells containing a change, a deletion or an addition) from v. 9.0 are marked yellow. Changed comments are underlined. Removed comments are shown in strikethrough font style.

General

• "Mecillinam" changed to "Mecillinam oral" • Imipenem-relebactam added • Delafloxacin added • HE superscript (high exposure for agent) removed and replaced with breakpoints which categorise wild-type organisms (organisms without phenotypically detectable acquired resistance mechanisms to the agent) as "Susceptible, increased exposure (I)" instead of "Susceptible, standard dosing regimen (S)". • For agents used to screen for resistance only, "screen" has been changed to "screen only" for clarification. Breakpoints related to the new definition of the I For several agents, EUCAST has introduced breakpoints which categorise wild-type organisms (organisms without phenotypically detectable acquired resistance mechanisms to the agent) as "Susceptible, increased exposure (I)" instead of "Susceptible, standard dosing regimen (S)". Some of these were introduced in v. 9.0 category and some in v. 10.0 (green highlights). From v. 10.0, susceptible breakpoints for these organism-agent combinations are listed as arbitrary, "off scale" breakpoints of S≤0.001 mg/L and S≥50 mm: • Enterobacterales : Cefazolin, cefuroxime iv and imipenem for Morganella morganii , Proteus spp. and Providencia spp. • Pseudomonas spp.: Piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanic acid, cefepime, ceftazidime, imipenem, aztreonam, ciprofloxacin and levofloxacin • Stenotrophomonas maltophilia : Trimethoprim-sulfamethoxazole • Acinetobacter spp.: Ciprofloxacin • Staphylococcus spp.: Ciprofloxacin, levofloxacin and ofloxacin • Enterococcus spp.: Imipenem • Streptococcus groups A, B, C and G: Levofloxacin • Streptococcus pneumoniae : Levofloxacin • Haemophilus influenzae : Amoxicillin oral, amoxicillin-clavulanic acid oral and cefuroxime oral • Moraxella catarrhalis : Cefuroxime oral • Burkholderia pseudomallei : Amoxicillin-clavulanic acid, ceftazidime, doxycycline, chloramphenicol and trimethoprim-sulfamethoxazole • Note 7 new Notes • Note 8 revised • Note 14 new • Updated information on breakpoints which categorise wild-type organisms as "Susceptible, increased exposure (I)" Guidance • New information on breakpoints in brackets • Information added for Streptococcus groups A, B, C and G Taxonomy • M. tuberculosis var. canetti removed in species list for M. tuberculosis complex Dosages General • New position in the breakpoint table • General text updated • Definition on uncomplicated UTI added • Dosages for uncomplicated UTI listed in a separate column. For some agents, there is only a dose for uncomplicated UTI • Comments on high dose removed when breakpoints categorise wild-type organisms as "Susceptible, increased exposure (I)" • Dosages of ceftazidime-avibactam and meropenem-vaborbactam are presented as a single dosing regimen because the approved dosage is designed to achieve maximum exposure New dosages • Imipenem-relebactam • Delafloxacin

1

Version 10.0, 2020-01-01 Dosages continued

Technical uncertainty Enterobacterales

Changes (cells containing a change, a deletion or an addition) from v. 9.0 are marked yellow. Changed comments are underlined. Removed comments are shown in strikethrough font style. Revised dosages • Amoxicillin oral • Amoxicillin-clavulanic acid oral • Mecillinam oral • Cefadroxil • Cefalexin • Cefazolin • Cefixime • Cefpodoxime • Ceftolozane-tazobactam (different doses depending on indication) • Ceftriaxone • Cefuroxime oral • Norfloxacin • Amikacin • Gentamicin • Netilmicin • Tobramycin • Tedizolid (iv dosage added) • Fosfomycin oral • Nitrofurantoin • Nitroxoline • Trimethoprim • Trimethoprim-sulfamethoxazole New comments • Amoxicillin-clavulanic acid oral • Clarithromycin Revised comments • Benzylpenicillin • Ceftriaxone • Ciprofloxacin ("+ combination" removed) • Ofloxacin ("+ combination" removed) • General updates in the text General • "Mecillinam" changed to "Mecillinam oral" • Mecillinam oral breakpoints valid also for Citrobacter spp. and Enterobacter spp. • Indication for ceftibuten changed from "UTI only" to "infections originating from the urinary tract" • New indications for aminoglycosides New breakpoints • Cefazolin (MIC) • Imipenem-relebactam (MIC) • Delafloxacin (MIC) • Eravacycline (zone diameter)

2

Version 10.0, 2020-01-01 Enterobacterales continued

Pseudomonas spp.

Changes (cells containing a change, a deletion or an addition) from v. 9.0 are marked yellow. Changed comments are underlined. Removed comments are shown in strikethrough font style. Revised breakpoints • Ceftolozane-tazobactam (MIC and zone diameter) • Cefuroxime iv (MIC and zone diameter) • Imipenem (S breakpoint changed to ≤0.001 mg/L for consistency) • Norfloxacin (MIC and zone diameter) • Amikacin (MIC and zone diameter) • Gentamicin (MIC and zone diameter) • Netilmicin (MIC and zone diameter) • Tobramycin (MIC and zone diameter) • Trimethoprim (MIC and zone diameter) New comments • Cephaloporins comment 4 • Carbapenems comment 3 • Fluoroquinolones comment 2/C • Fluoroquinolones comment D Revised comments • Penicillins comment 1 • Penicillins comment D • Aminoglycosides comment 1/A General • New indications for aminoglycosides New breakpoints • Imipenem-relebactam (MIC) Revised breakpoints • Piperacillin (MIC and zone diameter) • Piperacillin-tazobactam (MIC and zone diameter) • Ticarcillin (MIC and zone diameter) • Ticarcillin-clavulanic acid (MIC and zone diameter) • Cefepime (MIC and zone diameter) • Ceftazidime (MIC and zone diameter) • Imipenem (MIC and zone diameter) • Aztreonam (MIC and zone diameter) • Ciprofloxacin (MIC and zone diameter) • Levofloxacin (MIC and zone diameter) • Amikacin (MIC and zone diameter) • Gentamicin (MIC and zone diameter) • Netilmicin (MIC and zone diameter) • Tobramycin (MIC and zone diameter) ATUs added • Piperacillin (zone diameter) New comments • Cephalosporins comment 2 • Carbapenems comment 1 Revised comments • Aminoglycosides comment 1/A

3

Version 10.0, 2020-01-01 Stenotrophomonas maltophilia

Acinetobacter spp.

Staphylococcus spp.

Changes (cells containing a change, a deletion or an addition) from v. 9.0 are marked yellow. Changed comments are underlined. Removed comments are shown in strikethrough font style. Revised breakpoints • Trimethoprim-sulfamethoxazole (MIC and zone diameter) New comments • Miscellaneous agents comment B General • New indications for aminoglycosides New breakpoints • Imipenem-relebactam (MIC) Revised breakpoints • Ciprofloxacin (S breakpoint changed to ≤0.001 mg/L for consistency) • Amikacin (MIC and zone diameter) • Gentamicin (MIC and zone diameter) • Netilmicin (MIC and zone diameter) • Tobramycin (MIC and zone diameter) New comments • Carbapenems comment 1 Revised comments • Aminoglycosides comment 1/A General • Screening criteria for methicillin resistance in S. schleiferi added • Penicillin comment 2/C added to amoxicillin, piperacillin, ticarcillin and phenoxymethylpenicillin (coagulase-negative staphylococci) New breakpoints • Imipenem-relebactam (Note) • Delafloxacin (MIC) • Eravacycline (zone diameter) • Tedizolid (zone diameter) Revised breakpoints • Ciprofloxacin (MIC and zone diameter) • Levofloxacin (MIC and zone diameter) • Ofloxacin (MIC and zone diameter) • Amikacin (MIC and zone diameter) • Gentamicin (MIC and zone diameter) • Netilmicin (MIC and zone diameter) • Tobramycin (MIC and zone diameter) • Minocycline (MIC and zone diameter) • Tigecycline (zone diameter) • Trimethoprim (MIC and zone diameter) New comments • Cephalosporins comment 2 • Fluoroquinolones comment B • Tetracyclines comment B

4

Version 10.0, 2020-01-01 Staphylococcus spp. continued

Enterococcus spp.

Streptococcus groups A, B, C and G

Changes (cells containing a change, a deletion or an addition) from v. 9.0 are marked yellow. Changed comments are underlined. Removed comments are shown in strikethrough font style. Revised comments • Penicillins comment 1/A • Penicillins comment E • Cephalosporins comment 1/A • Fluoroquinolones comment C • Aminoglycosides comment 1/A • Glycopeptides comment 1 Removed comments • Oxazolidinones comment A • Oxazolidinones comment B New breakpoints • Eravacycline (zone diameter, separate breakpoints for E. faecalis and E. faecium ) Revised breakpoints • Imipenem (MIC and zone diameter) • Tigecycline (zone diameter, separate breakpoints for E. faecalis and E. faecium ) • Linezolid (zone diameter) New comments • Penicillins comment 1 Revised comments • Penicillins comment 2/A General • Information on taxonomy added New breakpoints • Imipenem-relebactam (Note) • Delafloxacin (MIC) • Tedizolid (zone diameter) Revised breakpoints • Oxacillin (Note added) • Meropenem-vaborbactam (Note added) • Levofloxacin (MIC and zone diameter) • Minocycline (MIC and zone diameter) • Linezolid (MIC and zone diameter) New comments • Cephalosporins comment 2 (lacking in previous versions) • Fluoroquinolones comment A Revised comments • Fluoroquinolones comment C • Oxazolidinones comment A

5

Version 10.0, 2020-01-01 Streptococcus pneumoniae

Viridans group streptococci

Changes (cells containing a change, a deletion or an addition) from v. 9.0 are marked yellow. Changed comments are underlined. Removed comments are shown in strikethrough font style. General • Flow chart updated New breakpoints • Imipenem-relebactam (Note) Revised breakpoints • Cefaclor (S breakpoint changed to ≤0.001 mg/L for consistency) • Meropenem-vaborbactam (Note added) • Levofloxacin (MIC and zone diameter) • Minocycline (MIC and zone diameter) • Linezolid (MIC and zone diameter) • Rifampicin (MIC) New comments • Penicillins comment 4 (lacking in previous versions) Revised comments • Penicillins comment 1/A • Cephalosporins comment 1/A • Carbapenems comment 1/A • Fluoroquinolones comment B New breakpoints • Imipenem-relebactam (MIC) • Delafloxacin (MIC) • Eravacycline (zone diameter) • Tedizolid (zone diameter) New comments • Carbapenems comment 1 • Fluoroquinolones comment A Removed comments • Oxazolidinones comment A

6

Version 10.0, 2020-01-01 Haemophilus influenzae

Moraxella catarrhalis

Neisseria gonorrhoeae

Neisseria meningitidis

Gram-positive anaerobes

Gram-negative anaerobes

Changes (cells containing a change, a deletion or an addition) from v. 9.0 are marked yellow. Changed comments are underlined. Removed comments are shown in strikethrough font style. General • Indication added for ceftolozane-tazobactam • Flow chart updated (amoxicillin-clavulanic acid added) • Pictures with reading example for beta-lactam agents added New breakpoints • Ceftolozane-tazobactam (MIC) Revised breakpoints • Ampicillin (zone diameter) • Amoxicillin oral (MIC and zone diameter) • Amoxicillin-clavulanic acid oral (MIC and zone diameter) • Cefuroxime oral (S breakpoint changed to ≤0.001 mg/L for consistency) • Minocycline (MIC and zone diameter) ATUs removed • Ampicillin (zone diameter) • Amoxicillin-clavulanic acid iv and oral (zone diameter) New comments • Penicillins comment B • Cephalosporins comment B • Carbapenems comment B • Carbapenems comment D Revised comments • Penicillins comment 1/A • Cephalosporins comment 1/A Revised breakpoints • Cefuroxime oral (S breakpoint changed to ≤0.001 mg/L for consistency) • Minocycline (MIC and zone diameter) General • "Surrogate agent" added to benzylpenicillin Revised breakpoints • Amoxicillin-clavulanic acid Revised comments • Penicillins comment 1 General • "Meningitis" added to chloramphenicol Revised breakpoints • Minocycline • Tetracycline New comments • Penicillins comment 1 • Miscellaneous agents comment 1 New breakpoints • Imipenem-relebactam New comments • Carbapenems comment 1 New breakpoints • Imipenem-relebactam New comments • Carbapenems comment 1 7

Version 10.0, 2020-01-01 Helicobacter pylori

Listeria monocytogenes Corynebacterium spp.

Burkholderia pseudomallei Burkholderia cepacia Legionella pneumophila Mycobacterium tuberculosis

Topical agents

PK-PD breakpoints

Changes (cells containing a change, a deletion or an addition) from v. 9.0 are marked yellow. Changed comments are underlined. Removed comments are shown in strikethrough font style. General • "Oral" added to amoxicillin Removed comments • Comment 1 for penicillins, fluoroquinolones, macrolides, tetracyclines and miscellaneous agents General • "iv" added to ampicillin Removed breakpoints • Gentamicin (MIC and zone diameter) New comments • Macrolides comment 1 • New table • New table (general information only) • New table (general information only) General • General information on breakpoints updated • Reference method for MIC determination added • Taxonomy updated Revised comments • Comment 1 General • New format. Clinical breakpoints removed and zone diameter screening cut-off values added • Tobramycin added New breakpoints • Imipenem-relebactam • Delafloxacin Revised breakpoints • Amikacin • Gentamicin • Tobramycin • Linezolid New comments • Carbapenems comment 1

8

European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters Version 10.0, valid from 2020-01-01 Notes 1. The EUCAST clinical breakpoint tables contain clinical MIC breakpoints (determined or revised during 2002-2019) and their inhibition zone diameter correlates. The EUCAST breakpoint table version 10.0 includes corrected typographical errors, clarifications, breakpoints for new agents and/or organisms, revised MIC breakpoints and revised and new zone diameter breakpoints. Changes are best seen on screen or on a colour printout since cells containing a change are yellow. New or revised comments are underlined. Removed comments are shown in strikethrough font style. 2. PK-PD (Non-species related) breakpoints are listed separately. 3. Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. 4. Antimicrobial agent names in blue are linked to EUCAST rationale documents. MIC and zone diameter breakpoints in blue are linked to EUCAST MIC and zone diameter distributions, respectively. 5. The document is released as an Excel® file suitable for viewing on screen and as an Acrobat® pdf file suitable for printing. To utilize all functions in the Excel® file, use Microsoft™ original programs only. The Excel® file enables users to alter the list of agents to suit the local range of agents tested. The content of single cells cannot be changed. Hide lines by right-clicking on the line number and choose "hide". Hide columns by right-clicking on the column letter and choose "hide". 6. EUCAST breakpoints are used to categorise results into three susceptibility categories: S - Susceptible, standard dosing regimen: A microorganism is categorised as Susceptible, standard dosing regimen, when there is a high likelihood of therapeutic success using a standard dosing regimen of the agent. I - Susceptible, increased exposure: A microorganism is categorised as Susceptible, increased exposure * when there is a high likelihood of therapeutic success because exposure to the agent is increased by adjusting the dosing regimen or by its concentration at the site of infection. R - Resistant: A microorganism is categorised as Resistant when there is a high likelihood of therapeutic failure even when there is increased exposure. *Exposure is a function of how the mode of administration, dose, dosing interval, infusion time, as well as distribution and excretion of the antimicrobial agent will influence the infecting organism at the site of infection. 7. For an agent and a species, the ECOFF (epidemiological cut-off value) is the highest MIC (or the smallest inhibition zone diameter) for organisms devoid of phenotypically detectable acquired resistance mechanisms. Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. 8. An MIC breakpoint of S ≤ 0.001 mg/L is an arbitrary, "off scale" breakpoint (corresponding to a zone diameter breakpoint of "S ≥ 50 mm") which categorises wild-type organisms (organisms without phenotypically detectable resistance mechanisms to the agent) as "Susceptible, increased exposure" (I). For these organism-agent combinations, never report “Susceptible, standard dosing regimen” (S). 9. For some organism-agent combinations, results may be in an area where the interpretation is uncertain. EUCAST has designated this an Area of Technical Uncertainty (ATU). It corresponds to an MIC value and/or zone diameter interval where the categorisation is doubtful. See separate page for more information on ATU and how to deal with results in the ATU. 10. In order to simplify the EUCAST tables, the "Susceptible, increased exposure" (I category) is not listed. It is interpreted as values between the S and the R breakpoints. For example, for MIC breakpoints listed as S ≤ 1 mg/L and R > 8 mg/L, the I category is 2-8 (technically >1-8) mg/L, and for zone diameter breakpoints listed as S ≥ 22 mm and R < 18 mm, the I category is 1821 mm. 9

Notes 11. For Escherichia coli with fosfomycin, Stenotrophomonas maltophilia with trimethoprim-sulfamethoxazole, Staphylococcus aureus with benzylpenicillin, enterococci with vancomycin, Aeromonas spp. with trimethoprim-sulfamethoxazole and Burkholderia pseudomallei with trimethoprim-sulfamethoxazole, it is crucial to follow specific reading instructions for correct interpretation of the disk diffusion test. For these, pictures with reading e...